Citi Upgrades Rigel Pharmaceuticals (RIGL) to Buy
Get Alerts RIGL Hot Sheet
Price: $42.58 +4.39%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citi upgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Neutral to Buy with a price target of $13.00.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $9.35 yesterday.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $9.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel launches breast cancer drug Veppanu at $29,400 per month
- TD Cowen Upgrades Northland Power Inc. (NPI:CN) (NPIFF) to Buy
- Keefe, Bruyette & Woods Upgrades Nayax (NYAX) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share